This relationship was reported to be partially driven by leptin, which is associated with an increase in the efficacy of PD-1/PD-L1 blockade, emphasizing that obesity can represent a valuable biomarker for certain cancer immunotherapies [16]. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.